WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organization (CRO) of Akoya Biosciences (Nasdaq: AKYA; “Akoya”). By combining Akoya's single-cell imaging solutions with BostonGene's unparalleled expertise in spatial proteomics sample processing and analysis, researchers will gain unprecedented access to the intricate landscape of cellular biology, paving the way for ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call. At this time, all participant ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.52%. A quarter ago, it was expected that this tissue analysis provider would post a loss of $0.37 per share when it actually produced a loss of $0.26, delivering a surprise of 29.73%.Over the last four quarters, the c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaw ...

Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023. "Akoya's successful 2023 performance reflects the high demand for our leading spatial biology solutions and effective ...

MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advan ...

Akoya Biosciences (AKYA) shares soared 7.4% in the last trading session to close at $5.96. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.7% gain over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor expectations regarding the company's financial performance in the fourth quarter of 2023. Akoya generates revenues from the sale of its products and services. Product revenues inclu ...

MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that the newly established Queensland Spatial Biology Centre (QSBC), located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated. The PhenoCycler-Fusion platform facilitates the understanding of the cellular compositions, neighbor ...

MARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the establishment of its Scientific Advisory Board (SAB) to provide strategic guidance and consult on the Company's efforts to deliver spatial biology solutions for the life sciences industry, from discovery to diagnostics. The initial members of Akoya's Scientific Advisory Board are: Garry Nolan, Ph.D., Rachford and Carlota A. Harris Professor in the Department of Path ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 8th:Akoya Biosciences, Inc. (AKYA) : This life-sciences technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.4% over the last 60 days.Akoya’s shares gained 11.9% over the last three months compared with the S&P 500’s advance of 8%. The company possesses a Momentum Score  of A.Alpha Tau Medical Ltd. (DRTS) : This clinical-sta ...